Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.

被引：3

作者：

Goyal, Lipika ^{[1
]}

Meric-Bernstam, Funda ^{[2
]}

Hollebecque, Antoine ^{[3
]}

Morizane, Chigusa ^{[4
]}

Valle, Juan W. ^{[5
]}

Karasic, Thomas B. ^{[6
]}

Abrams, Thomas A. ^{[7
]}

Kelley, Robin Kate ^{[8
]}

Cassier, Philippe ^{[9
]}

Furuse, Junji ^{[10
]}

Klumpen, Heinz-Josef ^{[11
]}

Chang, Heung-Moon ^{[12
]}

Chen, Li-Tzong ^{[13
]}

Komatsu, Yoshito ^{[14
]}

Masuda, Kunihiro ^{[15
]}

Ahn, Daniel ^{[16
]}

He, Yaohua ^{[17
]}

Soni, Nital ^{[18
]}

Benhadji, Karim A. ^{[17
]}

Bridgewater, John A. ^{[19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Inst Gustave Roussy, Villejuif, France

[4] Natl Canc Ctr, Tokyo, Japan

[5] Univ Manchester, Manchester, Lancs, England

[6] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Ctr Leon Berard, Lyon, France

[10] Kyorin Univ, Tokyo, Japan

[11] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[12] Asan Med Ctr, Seoul, South Korea

[13] Natl Inst Canc Res, Tainan, Taiwan

[14] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan

[15] Tohoku Univ, Sendai, Miyagi, Japan

[16] Mayo Clin, Phoenix, AZ USA

[17] Taiho Oncol Inc, Princeton, NJ USA

[18] Taiho Oncol, Princeton, NJ USA

[19] UCL, Canc Inst, London, England

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT010

引用

页数：2

共 50 条

[21] Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements
Neuzillet, Cindy
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 773 - 775
[22] FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements
Gandhy, Shruti U.
Casak, Sandra J.
Mushti, Sirisha L.
Cheng, Joyce
Subramaniam, Sriram
Zhao, Hong
Zhao, Miao
Bi, Youwei
Liu, Guansheng
Fan, Jianghong
Adeniyi, Oluseyi
Charlab, Rosane
Kufrin, Dubravka
Thompson, Matthew D.
Jarrell, Kristin
Auth, Doris
Lemery, Steven J.
Pazdur, Richard
Kluetz, Paul G.
Fashoyin-Aje, Lola A.
CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4027 - 4031
[23] Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
Schram, A.
Borad, M.
Sahai, V.
Kamath, S.
Kim, R.
Liao, C. Y. A.
Oh, D. Y.
Ponz-Sarvise, M.
Yachnin, J.
Shell, S. A.
Cassier, P.
Dotan, E.
Florou, V.
Moreno, V.
Park, J. O.
Tai, D.
Schmidt-Kittler, O.
Ferte, C.
Goyal, L.
Subbiah, V.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S116 - S116
[24] Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
Busset, M. Droz Dit
Shaib, W. L.
Mody, K.
Personeni, N.
Damjanov, N.
Harris, W. P.
Bergamo, F.
Brandi, G.
Masi, G.
Halfdanarson, T. R.
Tam, V.
Goff, L. W.
Knox, J.
Hollebecque, A.
Macarulla Mercade, T.
Cantero, F.
Saulay, M.
Braun, S.
Javle, M.
Borad, M.
ANNALS OF ONCOLOGY, 2021, 32 : S376 - S376
[25] Real-world genomic testing, treatment, and outcomes in patients with cholangiocarcinoma with FGFR2 fusions/rearrangements.
Borad, Mitesh J.
Conner, Therese
He, LiHong
Kazerooni, Reza
Salimi, Tehseen
Epstein, Robert S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16168 - E16168
[26] Cholangiocarcinoma patients with FGFR2 fusions/ rearrangements but primary refractory to pemigatinib: the real challenge?
Rizzo, A.
Ricci, A. D.
Brandi, G.
ESMO OPEN, 2024, 9 (10)
[27] FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma
Cao, Zi
Yang, Yichen
Liu, Shasha
Sun, Lin
Liu, Yanxue
Luo, Ye
Wang, Jian
Sun, Yan
JOURNAL OF GASTROENTEROLOGY, 2025, 60 (02) : 235 - 246
[28] MATCHING-ADJUSTED INDIRECT COMPARISON OF FUTIBATINIB VERSUS CHEMOTHERAPY AND PEMIGATINIB IN CHOLANGIOCARCINOMA PATIENTS WITH FGFR2 FUSIONS/REARRANGEMENTS
Paine, A.
Thom, H.
Wacheck, V
He, Y.
Kazerooni, R.
Salimi, T.
Borad, M. J.
Bridgewater, J.
VALUE IN HEALTH, 2022, 25 (12) : S33 - S33
[29] Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report
d'Arienzo, Paolo D.
MacDonald, Alan R.
Patel, Virjen
Ma, Yuk T.
Pihlak, Rille
Starling, Naureen
ONCOTARGETS AND THERAPY, 2024, 17 : 489 - 496
[30] Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Busset, M. Droz Dit
Braun, S.
El-Rayes, B.
Harris, W. P.
Damjanov, N.
Masi, G.
Rimassa, L.
Bhoori, S.
Niger, M.
Personeni, N.
Braiteh, F.
Lonardi, S.
Engelhardt, M.
Saulay, M.
Schwartz, B.
Shaib, W. L.
Mazzaferro, V.
Papadopoulos, K. P.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →